PUBLISHER: IMARC | PRODUCT CODE: 1701969
PUBLISHER: IMARC | PRODUCT CODE: 1701969
The global women's health diagnostics market size reached USD 31.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 54.2 Billion by 2033, exhibiting a growth rate (CAGR) of 6.4% during 2025-2033. The market is propelled by the rising number of individuals diagnosed with chronic and lifestyle-related diseases, significant technological developments in diagnostic services, increasing awareness about women's health through numerous campaigns and initiatives by the governments and public organizations, increasing acceptance rate of point-of-care diagnostics, and rapid growth in telemedicine and remote diagnostics industry.
Women's health diagnostics help diagnose various biological and psychosocial conditions of female patients. They assist in addressing sexual and vaginal issues and pregnancy complications and managing threatening diseases, such as osteoporosis, menopause, and certain cancers like breast and cervical. They rely on a series of advanced laboratory tests, tools, and procedures, which include biopsy, ultrasound, chemotherapy, and magnetic resonance imaging (MRI). Several healthcare diagnostics centers are currently offering an expansive range of laboratory testing solutions to enhance the diagnosis and management of rare diseases and conditions that affect women.
The rising prevalence of health issues that impact the overall well-being of women represents one of the major factors influencing the market positively. Moreover, the growing health consciousness, along with the increasing awareness about the benefits of early diagnosis, is catalyzing the demand for point-of-care (POC) women's health diagnostics across the globe. Apart from this, the rising rate of infertility on account of stressful lifestyles and the growing consumption of alcohol and drugs is driving the need for women's health diagnostics to address pregnancy complications and ensure a healthier life. Furthermore, as menopause can increase the risk of developing certain medical conditions, including cardiovascular diseases and urinary incontinence, a significant rise in the female population which is over 50 years is contributing to the market growth. Besides this, several research studies have concluded that women are more likely to experience psychiatric disorders, such as depression and anxiety, during hormonal changes. This, in confluence with several initiatives undertaken by health agencies of numerous countries to improve mental health of women, is propelling the market growth across the globe.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, bioMerieux SA, Cardinal Health Inc., Cook Group Incorporated, F. Hoffmann-La Roche AG, General Electric Company, Hologic Inc., Koninklijke Philips N.V., Perkinelmer Inc., Quest Diagnostics Inc., Siemens AG and Thermo Fisher Scientific Inc.